BERLIN (dpa-AFX) - The company founder and Chairman of the Supervisory Board of the radiation and medical technology specialist Eckert & Ziegler is moving from the parent company to the spin-off subsidiary for clinical activities. Andreas Eckert will step down from the Supervisory Board in the spring and join the Executive Board of the subsidiary Pentixapharm, the SDax-listed group announced in Berlin on Tuesday. Group Executive Board member Hakim Bouterfa, who is responsible for clinical development, will also move to Pentixapharm as a member of the Executive Board; his position on the management board of the parent company will be eliminated.

Eckert & Ziegler announced in October that it intended to spin off Pentixapharm and then concentrate on its position as a leading supplier of radioisotopes for the production of radiopharmaceuticals. The management of Pentixapharm will present details of the spin-off plans and the associated measures to Eckert & Ziegler shareholders this Monday (November 27) in Frankfurt./men/jha/